First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature

N G CHERNOVA; E E ZVONKOV; D S BADMAZHAPOVA; M N SINITSYNA; L A GREBENYUK; Y V SIDOROVA; I E KOSTINA; A M KOVRIGINA; T N OBUKHOVA; A B SUDARIKOV; V G SAVCHENKO

doi:10.26442/terarkh201890777-81

Терапевтический архив (Jul 2018)

First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature

N G CHERNOVA,
E E ZVONKOV,
D S BADMAZHAPOVA,
M N SINITSYNA,
L A GREBENYUK,
Y V SIDOROVA,
I E KOSTINA,
A M KOVRIGINA,
T N OBUKHOVA,
A B SUDARIKOV,
V G SAVCHENKO

Affiliations

N G CHERNOVA: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
E E ZVONKOV: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
D S BADMAZHAPOVA: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
M N SINITSYNA: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
L A GREBENYUK: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
Y V SIDOROVA: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
I E KOSTINA: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
A M KOVRIGINA: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
T N OBUKHOVA: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
A B SUDARIKOV: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation
V G SAVCHENKO: Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

DOI: https://doi.org/10.26442/terarkh201890777-81
Journal volume & issue: Vol. 90, no. 7
pp. 77 – 81

Abstract

Read online

Nodal anaplastic ALK-negative large cell lymphoma (nALCL, ALK-) is a Т-cell lymphoma that is characterized by aggressive clinical course and low sensitivity to СНОР (cyclophosphamide, doxorubicin, vincristine, prednisolone) and other chemotherapy regimen. In the article we present a literature review and describe our clinical case of nALCL, ALK-. For the first time a combination of Brentuximab vedotin with modified program NHL-BFM-90 was used as a first-line therapy. As a result of immunochemotherapy a complete antineoplastic effect was obtained. For consolidation of this effect high-dose chemotherapy with following autologous blood stem cell transplantation was performed. The chosen treatment tactics allowed to achieve a complete remission in a medium risk group patient.

Published in Терапевтический архив

ISSN: 0040-3660 (Print); 2309-5342 (Online)
Publisher: "Consilium Medicum" Publishing house
Country of publisher: Russian Federation
LCC subjects: Medicine
Website: http://ter-arkhiv.ru/en/

About the journal

Abstract

Keywords